Page 2 - Nse Nifty50 Benchmark Index

Nifty chart shows Golden Cross formation; will its 6-year history hold?

The Nifty has hit a new high in each of 5 occasions post formation of 'Golden Cross' on the daily chart since 2019, clocking an average gain of 24.4%; shows historical study.

Top stock picks by Motilal Oswal: Large, mid & small cap recommendations

Motilal Oswal reserach desk have suggested buying M&M, Bharti Airtel, PNB and others today; here's why

Nykaa shares slip 4% despite posting healthy Q4; Is it buying opportunity?

Nykaa share price slips 4 per cent in trade despite posting strong Q4 numbers; Check more details here

Nomura raises Nifty March 2026 target to 26,140 on supportive macros

The revised Nifty50 target implies a potential upside of about 6 per cent from current levels.

Shriram Properties share skyrockets 18% on robust Q4 results; details here

Shriram Properties shares were buzzing in trade on the back of a strong March quarter of financial year 2025 (Q4FY25) performance.

MOFSL projects 22% upside for this liquor stock; up 2% in weak market today

The uptick in Radico Khaitan shares came after domestic brokerage Motilal Oswal Financial Services Limited (MOFSL) initiated coverage on the stock with a 'Buy' rating.

Here's why Sumitomo Chemical India share price was under pressure today

Sumitomo Chemical India shares were under pressure due to weak March quarter of financial year 2025 (Q4FY25) results.

Bajaj Healthcare slips 9% on weak Q4 operational performance; details here

Bajaj Healthcare share price dropped today on the back of weak operational performance in the March quarter of FY25 (Q4FY25).

RateGain Travel share pops 6% on healthy Q4 results; check key numbers here

RateGain Travel share price rose on the back of robust March quarter of financial year 2025 (Q4FY25) results.

Here's why Patel Engineering share price rose 3% in trade today; details

Patel Engineering share rose after announcing that it, along with its joint venture (JV) partner, has secured a deal of ₹958.33 crore from the Maharashtra Krishna Valley Development Corporation, Pune

Biocon share rises as arm secures UK MHRA nod for plaque psoriasis drug

Biocon share rose after arm, Biocon Biologics, was granted market authorisation in the UK for Yesintek, a biosimilar of Ustekinumab, from the Medicines and Healthcare products Regulatory Agency (MHRA)

Sensex, Nifty favourably placed; these levels may shape market this week

Stock market weekly outlook: Technical charts indicate that the bias for the Sensex and Nifty is likely to remain positive as long as the indices sustain above 80,250 and 24,380, respectively.

What drove Indoco Remedies share price 6% higher today? Top details inside

Indoco Remedies' share price rose after the company received final USFDA approval for its ANDA to market Allopurinol tablets USP, 200 mg - a generic version of Zyloprim 200 mg by Casper Pharma LLC.

Sun Pharma share price slips 5% after Q4 results; check key numbers here

Sun Pharma share price dropped after the company posted a mixed bag of results in the March quarter of financial year 2025 (Q4FY25).

What sparked 13% jump in VRL Logistics share price today? Find out here

The rise in VRL Logistics share price came after the company posted strong Q4 results (March quarter).

VA Tech Wabag share rallies 10% on healthy Q4 nos; check key details here

VA Tech share price surged after the company reported strong results in the March quarter of financial year 2025 (Q4FY25).

NTPC Green share price zooms 12% on posting 188% rise in Q4 PAT YoY

NTPC Green Energy shares jump 12 per cent as the company posts healthy Q4 numbers

Here's why Nalco share price was buzzing in trade on May 22; details

Nalco shares surged after the company reported its highest-ever net profit and revenue from operations since inception in FY25.

J Kumar Infraprojects share price pops 4% as Q4 profit rises 15% YoY

J Kumar Infra share price rose on the back of healthy results in the March quarter of financial year 2025 (Q4FY25).

Zydus Life Q4 profit falls 1% YoY; ₹11 dividend declared; stock down 2%

Zydus Lifesciences consolidated net profit slipped about 1 per cent year-on-year (Y-o-Y) to ₹1,171 crore in the March quarter of financial year 2025 (Q4FY25), from ₹1,182 crore in Q4FY24.